19808-30-1

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
5-bromo-1H-pyrimidin-4-one is used as a key building block for the synthesis of pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic and pesticidal properties.
Used in DNA-Intercalating Agents Production:
In the field of molecular biology, 5-bromo-1H-pyrimidin-4-one is used as a component in the production of DNA-intercalating agents. These agents have the ability to bind between the base pairs of DNA, which can be utilized in various applications such as imaging, drug delivery, and gene regulation.
Used in Fluorescent Dyes Manufacturing:
5-bromo-1H-pyrimidin-4-one is also utilized in the manufacturing of fluorescent dyes. These dyes are important in various scientific and industrial applications, including cell biology, diagnostics, and as markers in various assays.
Used in Medicinal Chemistry and Drug Discovery:
Due to its structural features and reactivity, 5-bromo-1H-pyrimidin-4-one has potential applications in the field of medicinal chemistry and drug discovery. It can be used to develop new compounds with specific biological activities, contributing to the advancement of new treatments and therapies.

InChI:InChI=1/C4H3BrN2O/c5-3-1-6-2-7-4(3)8/h1-2H,(H,6,7,8)

Upstream product

• 51953-18-5 pyrimidine-4(3H)-one 
• 4595-59-9 5-bromopyrimidine 
• 51953-17-4 Pyrimidin-4-ol 
• 4319-85-1 5-bromo-4-methoxy-pyrimidine 

Downstream Products

• 56181-39-6 4-chloro-5-bromopyrimidine 
• 543726-87-0 5-bromo-3-(1-phenyl-2-pyrrolidin-1-yl-ethyl)-3H-pyrimidin-4-one 
• 1232361-96-4 4-(benzyloxy)-5-bromopyrimidine 
• 4319-85-1 5-bromo-4-methoxy-pyrimidine 
• 936635-88-0 5-bromo-3-(4-methoxybenzyl)pyrimidin-4(3H)-one 
• 14248-02-3 5-bromo-3-methyl-4-pyrimidone 

Relevant academic research and scientific papers

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones

Numerous potent P2X3 antagonists have been discovered and the therapeutic potential of P2X3 antagonism already comprises proof-of-concept data obtained in clinical trials with the most advanced compound. We have lately reported the discovery and optimization of thia-triaza-tricycle compounds with potent P2X3 antagonistic properties. This Letter describes the SAR of a back-up series containing a 4-oxo-quinazoline central ring. The discovery of the highly potent compounds 51 is presented.

IMIDAZOPYRROLIDINONE COMPOUNDS

The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

PYRROLOPYRROLIDINONE COMPOUNDS

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.

Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors

A pyridazin-4-one fragment 4 (hCatS IC50 = 170 μM) discovered through Tethering was modeled into cathepsin S and predicted to overlap in S2 with the tetrahydropyridinepyrazole core of a previously disclosed series of CatS inhibitors. This fragment served as a template to design pyridazin-3-one 12 (hCatS IC50 = 430 nM), which also incorporates P3 and P5 binding elements. A crystal structure of 12 bound to Cys25Ser CatS led to the synthesis of the potent diazinone isomers 22 (hCatS IC50 = 60 nM) and 27 (hCatS IC50 = 40 nM).

Heterobicyclic pyrazole compounds and methods of use

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.